

Press release 2023-09-01

(Retransmission) AcuCort signs partnership agreement for the four major Nordic countries with Unimedica Pharma

Retransmission of the press release that was published, with the associated MAR label, on August 31, 2023, at 17:35 CET.

AcuCort AB has today signed a partnership agreement for Sweden, Norway, Denmark and Finland with Unimedica Pharma. The agreement means that Unimedica will be responsible for sales and marketing of AcuCort's oral film Zeqmeli[®] in these countries.

With the agreement, AcuCort enters the commercialization phase that the company has been preparing for a long time. Previously, the company's oral film Zeqmeli[®] has received approval from pharmaceutical authorities in Sweden, Denmark, Norway and Finland, which allows for a commercial venture in these countries.

"The agreement with Unimedica Pharma is important for our success in the Nordic markets. Unimedica Pharma is a very reputable company with specialist expertise in the sales and marketing of pharmaceuticals in the Nordics, which we now benefit from as AcuCort enters a new chapter on its growth journey", says AcuCort's CEO Jonas Jönmark.

Unimedica Pharma's CEO Johan Frödin says in a comment:

"We have followed AcuCort for a long time and have been impressed by the innovative power that exists in the company. Zeqmeli is a product that fits well into our range and contributes to our vision of enabling a better life. We look forward to the collaboration with AcuCort and have great expectations for the launch of Zeqmeli on the Nordic markets."

For further information please contact:

Jonas Jönmark, CEO, AcuCort AB

Phone: 070 365 5400

E-mail: jonas.jonmark@acucort.se

About Unimedica Pharma

Unimedica Pharma is a Swedish specialist pharmaceutical company that today supplies the Nordics and Northern Europe with a wide range of medicines in several therapeutic areas. The business is divided into three main business areas: Registered specialist medicines, Licensed medicines, Contract manufacturing (CDMO). The company's head office is in Solna and the company is a wholly owned subsidiary of MedCap AB (publ), which is listed on Nasdaq Stockholm Mid Cap. Read more at: www.unimedica.se.

About AcuCort AB (publ)

AcuCort has developed and commercializes Zeqmeli[®], a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need supplemental oxygen therapy. Zeqmeli[®] is approved in Sweden, Denmark, Norway and Finland. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.